SCHEMBL23210814

SCHEMBL23210814

COc1cc2c(nc1-c1cccc3c1CCC3)c(-c1ccc(C(C)=O)nc1)nn2C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.36
AKT2 P31751 1/20 0.36
RORC P51449 1/20 0.33
IDO1 P14902 3/20 0.32
TTK P33981 3/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
JAK2 O60674 2/20 0.32
JAK1 P23458 2/20 0.32
TYK2 P29597 2/20 0.32
JAK3 P52333 2/20 0.32
PTGIR P43119 1/20 0.31
PTGDR Q13258 1/20 0.31
SCN9A Q15858 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
RXRA P19793 1/20 0.31
GYS1 P13807 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211071 0.90 STAT3 (0.33) AKT1AKT2TTK
SCHEMBL30308837 0.90 STAT3 (0.33) AKT1AKT2TTK
SCHEMBL29907072 0.90 STAT3 (0.33) AKT1AKT2TTK
SCHEMBL23211084 0.89 GYS1 (0.33) RORCIDO1JAK2JAK1TYK2
SCHEMBL23210935 0.85 SCN9A (0.33) RORCPTGIRPTGDRSCN9ANPC1
SCHEMBL23211042 0.81 MEN1 (0.37) RORCIDO1ALDH1A1GAAMEN1
SCHEMBL29907209 0.79 TNF (0.36) JAK2JAK1TYK2JAK3PTGIR
SCHEMBL23211054 0.79 TNF (0.36) JAK2JAK1TYK2JAK3PTGIR
SCHEMBL23236585 0.78 TTK (0.32) TTKJAK2JAK1TYK2JAK3
SCHEMBL23211050 0.76 SCN9A (0.32) SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US disclosed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 US disclosed
EP-4045151-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-08-24 EP disclosed
WO-2021076602-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-04-22 WO disclosed
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 AKT1 2001/4885AKT2 2020/4885RORC 371/4885
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 AKT1 2001/4885AKT2 2020/4885RORC 371/4885
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 AKT1 2001/4885AKT2 2020/4885RORC 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.